Assoc. Prof. Dr. Chih-Pin Chuu | Prostate Cancer Research | Best Researcher Award

Associate Investigator at Institute of Cellular and System Medicine, National Health Research Institutes, Taiwan.

Dr. Chih-Pin Chuu is an Associate Investigator at the Institute of Cellular and System Medicine, National Health Research Institutes (NHRI), Taiwan, with joint appointments at several leading Taiwanese universities. He received his Ph.D. in Cancer Biology from the University of Chicago, and his B.S. in Physics with a minor in Life Sciences from National Tsing Hua University. His research focuses on the molecular mechanisms of prostate cancer progression and therapeutic resistance, with an emphasis on hormone therapy, cancer metabolism, and natural product-based treatment strategies. Dr. Chuu has published extensively in peer-reviewed journals and leads multiple interdisciplinary and translational projects funded by Taiwan’s NSTC. His contributions to cancer biology have been recognized with prestigious awards such as the National Innovation Award (2021) and NHRI Young Investigator Award (2017).

Publication Profile

Scopus

Google Scholar

Educational Details

• Ph.D. in Cancer Biology, The University of Chicago, USA (2000–2005)

• B.S. in Physics, National Tsing Hua University, Taiwan (1993–1997)

  • Minor: Life Sciences

Professional Experience

Dr. Chuu currently holds multiple academic and research positions:

• Associate Investigator, Institute of Cellular and System Medicine, NHRI (2015–present)

• Supervisor PI, Micro-Western Array Core Lab, NHRI (2010–present)

• Adjunct Associate Professor, Graduate Institute of Clinical Medicine, Kaohsiung Medical University (2025–present)

• Associate Professor (Joint Appointment), Department of Life Sciences, National Central University (2021–present)

• Associate Investigator (Joint Appointment), National Defense Medical Center (2016–present)

• Assistant/Associate Professor (Joint Appointment), China Medical University (2013–present)

• Assistant/Associate Professor (Joint Appointment), National Chung Hsing University (2011–present)

Previous Roles Include:

• Assistant Investigator, NHRI (2009–2015)

• Postdoctoral Scholar, University of Chicago (2005–2009)

• Acting Chief, Student Affairs Office, NHRI (2020–2022)

• Academic Editor, PLOS ONE (2013–2021)

Research Interest

• Prostate cancer biology, drug resistance in second-generation hormone therapies

• Molecular oncology, cancer metabolism, tumor stemness and metastasis

• Biomarker discovery, high-throughput proteomic profiling using Micro-Western Arrays

• Natural products (e.g., green propolis, rooibos) in cancer prevention and treatment

• Translational medicine, integrating clinical and proteogenomic data for diagnostics

Author Metrics

Name: Assoc. Prof. Dr. Chih-Pin Chuu

• Total Citations: 4,443

• h-index: 34

• i10-index: 73

• Total Publications: 100+

• Most Cited Publication:

  • Ciaccio MF, Wagner JP, Chuu CP, et al. Nature Methods. 2010; 7(2):148–155 — 239 citations

• Top Publishing Journals:

  • Cancer Research, Nature Methods, Oncogene, Cancer Prevention Research, Cell Death & Disease

Top Noted Publication

1. Systems analysis of EGF receptor signaling dynamics with microwestern arrays

Authors: M.F. Ciaccio, J.P. Wagner, C.P. Chuu, D.A. Lauffenburger, R.B. Jones
Journal: Nature Methods, 7(2), 148–155
Year: 2010
Citation Count: 239
Summary: Introduced a novel high-throughput microwestern platform to analyze EGF receptor signaling dynamics; significant for systems biology and proteomic analysis.
Author role: Contributing author

2. Antiproliferative effect of liver X receptor agonists on LNCaP human prostate cancer cells

Authors: J. Fukuchi, J.M. Kokontis, R.A. Hiipakka, C. Chuu, S. Liao
Journal: Cancer Research, 64(21), 7686–7689
Year: 2004
Citation Count: 202
Summary: Demonstrated the ability of LXR agonists to inhibit proliferation in prostate cancer cells.
Author role: Co-author

3. Identification of thioridazine, an antipsychotic drug, as an antiglioblastoma and anticancer stem cell agent using public gene expression data

Authors: H.W. Cheng, Y.H. Liang, Y.L. Kuo, C.P. Chuu, C.Y. Lin, M.H. Lee, A.T.H. Wu, et al.
Journal: Cell Death & Disease, 6(5), e1753
Year: 2015
Citation Count: 167
Summary: Used bioinformatics and gene expression profiling to reposition thioridazine as an anticancer stem cell therapy.
Author role: Contributing author

4. Inhibition of tumor growth and progression of LNCaP prostate cancer cells in athymic mice by androgen and liver X receptor agonist

Authors: C. Chuu, R.A. Hiipakka, J.M. Kokontis, J. Fukuchi, R.Y. Chen, S. Liao
Journal: Cancer Research, 66(13), 6482–6486
Year: 2006
Citation Count: 151
Summary: Showed that LXR agonists combined with androgen inhibit tumor growth in vivo.
Author role: First author

5. Caffeic acid phenethyl ester suppresses the proliferation of human prostate cancer cells through inhibition of p70S6K and Akt signaling networks

Authors: C.P. Chuu, H.P. Lin, M.F. Ciaccio, J.M. Kokontis, R.J. Hause Jr, R.A. Hiipakka, et al.
Journal: Cancer Prevention Research, 5(5), 788–797
Year: 2012
Citation Count: 150
Summary: Explored anticancer mechanisms of CAPE in prostate cancer, linking it to mTOR and Akt pathway inhibition.
Author role: First author

6. Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice

Authors: C. Chuu, R.A. Hiipakka, J. Fukuchi, J.M. Kokontis, S. Liao
Journal: Cancer Research, 65(6), 2082–2084
Year: 2005
Citation Count: 136
Summary: Reversal of castration resistance in prostate cancer by androgen reintroduction, proposing a paradoxical therapeutic approach.
Author role: First author

7. ASPM promotes prostate cancer stemness and progression by augmenting Wnt–Dvl-3–β-catenin signaling

Authors: V.C. Pai, C.C. Hsu, T.S. Chan, W.Y. Liao, C.P. Chuu, W.Y. Chen, C.R. Li, C.Y. Lin, et al.
Journal: Oncogene, 38(8), 1340–1353
Year: 2019
Citation Count: 135
Summary: Identified ASPM as a cancer stemness regulator via Wnt/β-catenin signaling in prostate cancer.
Author role: Co-author

8. Caffeic acid phenethyl ester is a potential therapeutic agent for oral cancer

Authors: Y.Y. Kuo, W.T. Jim, L.C. Su, C.J. Chung, C.Y. Lin, C. Huo, J.C. Tseng, S.H. Huang, C.P. Chuu, et al.
Journal: International Journal of Molecular Sciences, 16(5), 10748–10766
Year: 2015
Citation Count: 124
Summary: Showed CAPE’s effectiveness in oral squamous cell carcinoma via inhibition of proliferation and migration.
Author role: Co-author

9. Antiproliferative effect of LXR agonists T0901317 and 22(R)-hydroxycholesterol on multiple human cancer cell lines

Authors: C.P. Chuu, H.P. Lin
Journal: Anticancer Research, 30(9), 3643–3648
Year: 2010
Citation Count: 120
Summary: Demonstrated the broad antiproliferative activity of LXR agonists across various cancer types.
Author role: First author

10. Modulation of liver X receptor signaling as novel therapy for prostate cancer

Authors: C.P. Chuu, J.M. Kokontis, R.A. Hiipakka, S. Liao
Journal: Journal of Biomedical Science, 14, 543–553
Year: 2007
Citation Count: 118
Summary: A review highlighting LXR modulation as a potential therapeutic avenue in prostate cancer.
Author role: First author

Conclusion

Assoc. Prof. Dr. Chih-Pin Chuu stands out as a highly qualified and deserving candidate for the Best Researcher Award. His interdisciplinary research, particularly in the molecular mechanisms of cancer progression, therapeutic resistance, and natural compound-based interventions, has had a meaningful influence on cancer and cardiovascular-related biomedical science.

His record of scientific excellence, innovation, and sustained impact across academia and translational platforms make him a strong contender for this honor. With continued emphasis on global collaboration and clinical translation, his work is well-positioned to drive significant advancements in the field of oncology and beyond.